Home › Laryngeal Cancer › California › Orange
Laryngeal Cancer clinical trials in Orange, CA
4 studies for Laryngeal Cancer are looking for participants at sites in and around Orange (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
RecruitingPhase 2
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
RecruitingPhase 2
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
RecruitingPhase 2
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Orange
Laryngeal Cancer trials in other cities
- Atlanta, GA8 studies
- Chicago, IL8 studies
- Milwaukee, WI8 studies
- Kansas City, MO7 studies
- St. Louis, MO7 studies
- Portland, OR7 studies
- Richmond, VA6 studies
- Edison, NJ6 studies
- Baltimore, MD6 studies
- Cincinnati, OH6 studies
- Durham, NC6 studies
- Pittsburgh, PA6 studies
Other studies in Orange
- Non-Small Cell Lung Cancer25 studies
- Metastatic Cancer20 studies
- Colorectal Cancer16 studies
- Ovarian Cancer16 studies
- Pancreatic Cancer15 studies
- Melanoma14 studies
- Liver Cancer (Hepatocellular Carcinoma)14 studies
- Breast Cancer14 studies
- Lung Cancer14 studies
- Prostate Cancer14 studies
- Stomach Cancer13 studies
- Cancer (all types)13 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.